Page 5 - Dr Reddys

Dr Reddy's, Pharmazz ink licence pact to commercialise resuscitative agent

With this agreement, India will become the first global territory where Centhaquin (Lyfaquin) is being launched immediately, according to the company

Dr Reddy's Lab Q3 results: Net profit rises 11% on strong US, EU sales

For the Indian business in Q3 FY24, the revenue stood at Rs 1,180 crore Y-o-Y with a growth of 5 per cent and a sequential decline of 1 per cent

Dr Reddy's Lab Q3 results: PAT up 11%, beats estimates on strong US sales

The Hyderabad-based drug major had reported a net profit of Rs 1,247 crore for the October-December quarter of the last fiscal

Dr Reddy's recalls 8,000 bottles of generic drug in US over packaging error

Dr Reddy's Laboratories is recalling over 8,000 bottles of a generic medication used to prevent rejection of a transplanted organ from the US market due to a packaging error, according to the US Food & Drug Administration. The Hyderabad-based drug major is recalling 8,280 bottles of Tacrolimus capsules from the US market for "presence of foreign tablets/capsules" in the affected lot. One 0.5 mg Tacrolimus capsule was found in a bottle of 1 mg Tacrolimus capsules, the USFDA stated in its latest Enforcement Report. The affected lot was produced at Dr Reddy's Bachupally-based plant near Hyderabad. New Jersey-based Dr Reddy's Laboratories, Inc has initiated the nationwide (US) Class II recall on December 15, 2023. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Dr Reddy'

Dr Reddy's becomes 1st Indian pharma firm on Dow Jones Sustainability index

Dr. Reddy's Laboratories Ltd on Thursday said it has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda. Dr. Reddy's has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023, a press release from the drug maker said. Alongside its debut in DJSI World, the company retains its place in the Dow Jones Sustainability Index for Emerging Markets (DJSI EM) for the eighth year in a row based on Dr. Reddy's performance in the Standard & Poor Global Corporate Sustainability Assessment (S&P Global CSA) and additional screening criteria. Separately, Dr. Reddy's has been awarded Gold Medal' status by EcoVadis, the global sustainability ratings agency, for its score of 70 out of 100 in its scorecard for 2023. G V Prasad, Co-Chairman & Managing Director, Dr. Reddy's, said: As a company with over two decades of ...

A dose of concern for DRL: Sinks 5% on USFDA 'imminent' warning

Sell-off in response to a brokerage report, raising concerns about a warning on DRL's FTO 3

Dr Reddy's, Coya Therapeutics ink licensing agreement for ALS cure drug

Dr Reddy's Laboratories on Wednesday said its unit has inked a licensing agreement with Coya Therapeutics Inc to develop a combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). Dr Reddy's Laboratories SA and Coya have entered into a development and license agreement for the development and commercialisation of COYA 302, an investigational combination therapy for ALS, the Hyderabad-based drugmaker said in a statement. As per the terms of the agreement, Coya has granted Dr Reddy's an exclusive licence to commercialise COYA 302 in the US, Canada, the European Union and the UK for ALS. Coya retains the right to commercialise COYA 302 in Japan, Mexico, and each country in South America. As per the agreement, Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the US. As per the deal, Dr Reddy's will make a USD 7.5 million upfront payment to Coya. Upon the first FDA ...

Dr Reddy's, Glenmark recall products in US due to manufacturing issues

Dr Reddy's Laboratories, Glenmark Pharma and Zydus are recalling products in the US market for manufacturing issues, according to the US Food and Drug Administration (USFDA). In its latest enforcement report, the US health regulator said Princeton-based Dr Reddy's Laboratories, Inc, a unit of the Hyderabad-based drug firm, is recalling 1,656 bottles of Montelukast sodium tablets. The product is indicated to prevent wheezing, breathing difficulty, chest tightness, and coughing caused by asthma in adults. As per the USFDA, the company is recalling the affected lot due to "the presence of foreign tablets and capsules." A foreign tablet was found in a bottle of Montelukast sodium tablets, USP 10mg, identified as metoprolol 25 mg, it added. The company initiated the Class II voluntary recall on October 13 this year. The USFDA noted that Mahwah-based Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharma, is recalling 5,856 bottles of Deferasirox tablets for oral ...

Sensex drops 326 pts, Nifty below 19,450; PSBs, metals rally, IT sinks

Closing Bell on November 13, 2023: SBI Life, Bajaj Finance, Grasim, Infosys, Nestle India, Apollo Hospitals, Tech M, ICICI Bank, and HDFC Bank were the top laggards

Stocks to Watch: Reliance, Ultratech Cement, AU SFB, NTPC, Gujarat Gas, MGL

Stocks to watch on October 30, 2023: Fincare Small Finance Bank is set to merge with AU Small Finance Bank (AU SFB) in an all-share deal; Gujarat Gas has hiked industrial gas price to Rs 45.6 per scm

Dr Reddy's Q2 results: Net profit after tax rises 33% to Rs 1,482 crore

Consolidated quarterly revenue rose 9% to 69.03 billion rupees led by a 9% growth in the key global generics segment

Max Fin, JSP, Oberoi: Strategy for stocks with highest F&O rollover to Nov

Dr.Reddy's, Apollo Tyres and Jindal Steel are among the five stocks which have seen rollovers of up to 88 per cent to the November series.

Stocks to Watch: Dr Reddy's, Mazagon Dock, Adani Ports, Concor, Inox Green

Stocks to Watch on October 10, 2023: CLSA said that the war presented an even better buying opportunity in Adani Ports

Stocks to Watch: Tech M, Axis Bank, Dr Reddy's, RVNL, M&M, RBL Bank, AMCs

Stocks to watch on July 27, 2023: The govt is going to sell up to a 3.4 per cent stake in Rail Vikas Nigam with an option to additionally sell 1.96 per cent stake via an OFS

Global spending on Covid predicted to touch $500 bn by 2027: Dr Reddy's

Though the World Health Organisation lifted the emergency tag on COVID-19, global spending on the disease, including research to improve the understanding of long-term complications and the presence of post-acute sequels of the killer virus, is expected to touch USD 500 billion by 2027, pharma major Dr Reddy's Laboratories has said in its latest annual report. The report, released on Monday, further said the health systems have responded well by developing vaccines with significant efficacy, safety, and speed. However, with the inconsistent use of vaccines and therapeutics, the next few years are not without uncertainties, especially with the periodic emergence of infections and viral variants. "At the same time, research has been ongoing to improve the understanding of the long-term complications and the presence of post-acute sequels of COVID-19. Considering this, it is believed that COVID-19 will still be a major driver for global medicine spending in the coming years. Global ...

Dr Reddy's to enhance presence in emerging segments like nutraceuticals

Dr Reddy's Laboratories is looking to enhance its presence in various emerging segments like nutraceuticals and aims to get into integrated digital healthcare services as part of its future growth plans. In its Annual Report for 2022-23, the Hyderabad-based drug major informed the shareholders that it also intends to follow a disciplined approach towards cash management and acquisitions. "We are exploring business spaces that we think will shape the healthcare of the future. These include deepening our presence in nutraceuticals, cell and gene therapy and new chemical entities (NCEs)," Dr Reddy's Laboratories Chairman K Satish Reddy said. The drug firm is also exploring new spaces such as integrated digital healthcare services, digital therapeutics, and disease management, he added. "While these are long gestation businesses, and we are early in their development, we have made some progress," Reddy said. The drug firm informed the shareholders that it has a strategy in place which

Over one-third Nifty50 stocks look weak on charts. Time to be cautious?

Among banking majors, Axis Bank, ICICI Bank, HDFC Bank and State Bank of India (SBI) appear on track to hit new all-time high in the weeks ahead, charts suggest

Dr Reddy's Labs sinks 7% on disappointing Q4 operating performance

In Q4, the company's North America's revenue declined 17 per cent QoQ to Rs 2,530 crore, due to fluctuations in demand for new launches.

Sensex climbs 179 pts in fag-end, Nifty tops 18,300; auto, bank stocks lead

CLOSING BELL: The fag-end rally was powered by IndusInd Bank, Bajaj Finance, Tata Motors, Reliance Industries, HDFC Bank, Maruti Suzuki, and Bajaj Finserv

Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's

Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings